Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

Inclusion Criteria21

• Participants voluntarily provided written informed consent for this trial;
• Aged 18 to 80 years, inclusive, regardless of gender;
• With stable vital signs;
• Diagnosis of SBS-IF, confirmed by existing medical/surgical records, receiving parenteral nutrition (PN) due to surgical resection of the small intestine (<200 cm from the duodenojejunal flexure), and meeting one of the following criteria:
• Colon continuity maintained without jejunal/ileal stoma (Type II or III);
• Presence of a jejunostomy or ileostomy (Type I);
• Expected requirement of PN for more than 4 weeks, with an average PN caloric intake ≥80%;
• Ability to comply with the medication dosing and visit schedule;
• Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively;
• No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection;
• No history of drug abuse;
• Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants);
• No participation in any other drug trials (including the investigational product in this study) within three months prior to enrollment.
• Poor general condition, inability to accurately describe symptoms, presence of severe infection, respiratory insufficiency, or other conditions that may hinder active cooperation;
• History of allergic diseases, allergic constitution, or hypersensitivity to drugs structurally related to the investigational product;
• Patients with malignancy at any site;
• Those with psychiatric disorders, inability to cooperate, or impaired consciousness;
• Patients with contraindications to the investigational drug (including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2);
• Immunodeficiency, or current use of immunosuppressants or corticosteroids;
• Immediate family members of the sponsor, investigator, or study staff directly involved in the trial;
• Any other condition considered by the investigator as grounds for exclusion.